meta:
  schema_version: '1.0'
  compatible_engine: cellswarm>=2.0
combination_id: pembro_olaparib
components:
- pembrolizumab
- olaparib
clinical_trial: MEDIOLA / KEYLYNK-009
indication: BRCA+ TNBC
interaction_model: bliss_independence
synergy_rules:
  CD8_T:
    synergy_factor: 1.3
    affected_parameters:
    - activation
    - exhaustion
    notes: PARP inhibition activates STING → IFN → enhanced anti-PD-1
  Tumor:
    synergy_factor: 1.35
    affected_parameters:
    - apoptosis_susceptibility
    - immune_evasion
    notes: Synthetic lethality + immune attack
  Treg:
    synergy_factor: 1.0
    affected_parameters: []
  Macrophage:
    synergy_factor: 1.15
    affected_parameters:
    - polarization
  NK:
    synergy_factor: 1.1
    affected_parameters:
    - activation
  B_cell:
    synergy_factor: 1.0
    affected_parameters: []
toxicity_interaction:
  irAE_probability: 0.25
  dose_adjustment: 0.9
cancer_specific_modifiers:
  TNBC:
    efficacy_modifier: 1.3
    notes: BRCA+ TNBC strong rationale
  Melanoma:
    efficacy_modifier: 0.5
    notes: Limited HRD
  NSCLC:
    efficacy_modifier: 0.4
    notes: Limited HRD
  CRC-MSI-H:
    efficacy_modifier: 0.5
    notes: Some HRD overlap
  CRC-MSS:
    efficacy_modifier: 0.2
    notes: Low HRD
  Ovarian:
    efficacy_modifier: 1.2
    notes: BRCA+ HGSOC strong rationale
references:
- description: 'MEDIOLA: Durvalumab+Olaparib in BRCA+ cancers. Domchek et al. Lancet Oncol 2020'
  pmid: '32771088'
  verified: true
